is expressed throughout the cardiovascular system and is able to dilate vessels. This study investigated whether mechanical forces generated by changes in regional perfusion influence PTHrP release from the coronary vascular bed. Experiments were performed in vitro on saline-perfused rat hearts or isolated coronary endothelial cells exposed to cyclic strain and in vivo in anesthetized pigs. In vitro, PTHrP release from saline-perfused rat hearts was strongly correlated with coronary flow (r ϭ 0.84). Increasing coronary flow from 5 to 10 ml/min increased PTHrP release from 442 Ϯ 42 to 1,563 Ϯ 167 pg/min. Increasing the viscosity of the perfusate did not change basal PTHrP release. Increasing flow without a concomitant increase in pressure did not lead to an increase in release rate, but reduction in pressure under flow-constant conditions reduced PTHrP release rate. Cyclic strain induced a strain-dependent release of PTHrP from endothelial cells that was inhibited by the addition of a calcium-chelating agent. In vivo, there was a net release of PTHrP in the coronary circulation and decreases in coronary flow and pressure decreased the PTHrP release rate. Bradykinin in the presence of constant pressure increased PTHrP release, probably by increasing the intracellular calcium concentration in coronary endothelial cells. In summary, mechanical forces evoked by blood flow can trigger a constant PTHrP release. shear stress; endothelium; nitric oxide CORONARY ENDOTHELIUM PRODUCES several vasoactive factors that are involved in the regulation of coronary vasodilatation, i.e., nitric oxide (NO), prostacyclin, endothelium-derived hyperpolarizing factor (EDHF), and parathyroid hormone-related peptide (PTHrP). Initially, it was demonstrated that intracoronary injection of synthetic parathyroid hormone (PTH), which shares structural similarities with PTHrP, evoked an increase in coronary flow in the canine heart (4, 5). In a subsequent study in rat hearts, PTHrP increased coronary flow and appeared to be more potent than PTH (13). This observation is of particular interest, because PTHrP is expressed in human and rat fetal and adult hearts (2, 6), especially in coronary endothelial cells (17).
shear stress; endothelium; nitric oxide CORONARY ENDOTHELIUM PRODUCES several vasoactive factors that are involved in the regulation of coronary vasodilatation, i.e., nitric oxide (NO), prostacyclin, endothelium-derived hyperpolarizing factor (EDHF), and parathyroid hormone-related peptide (PTHrP). Initially, it was demonstrated that intracoronary injection of synthetic parathyroid hormone (PTH), which shares structural similarities with PTHrP, evoked an increase in coronary flow in the canine heart (4, 5) . In a subsequent study in rat hearts, PTHrP increased coronary flow and appeared to be more potent than PTH (13) . This observation is of particular interest, because PTHrP is expressed in human and rat fetal and adult hearts (2, 6) , especially in coronary endothelial cells (17) .
The physiological function of PTHrP released from coronary endothelial cells is not yet understood. We have recently begun to investigate the mechanisms of production and release of PTHrP by coronary endothelial cells. In a model of cultured endothelial cells, PTHrP was not released under static no-flow conditions unless the cells were energy depleted (17) . In contrast to the isolated cell system, PTHrP was constantly released from the coronary circulation of welloxygenated isolated, saline-perfused rat hearts. We hypothesized, therefore, that PTHrP might be released from the coronary vessels in a mechanosensitive manner. This hypothesis was investigated in the present study in vitro and in vivo, using isolated, perfused rat hearts, isolated coronary endothelial and smooth muscle cells that were exposed to cyclic strain, and in situ hearts of anesthetized pigs. Because NO is released in a flowdependent manner (8) , we also investigated whether endogenous basal NO release interacts with PTHrP release, as shown previously for NO and EDHF (1) .
METHODS
Heart perfusions. In vitro experiments were performed in isolated, saline-perfused rat hearts as described previously (18) . Hearts from 200-to 250-g male Wistar rats were mounted on a Langendorff perfusion system in a temperature-controlled chamber (37°C). The chamber was filled with humidified air during perfusion of hearts at 37°C and a flow rate of 5 ml/min for an initial stabilizing period of 5 min. Hearts were perfused with an oxygenated saline medium [composition of the perfusate (in mmol/l): 120.0 NaCl, 24.0 NaHCO 3, 27 KCl, 0.4 NaH2PO4, 1.0 MgCl2, 1.8 CaCl2, and 5.0 glucose, gassed with 95% O 2-5% CO2, pH 7.4] . The hearts were perfused under constant-flow conditions, and coronary flow was varied between 1.25 and 10 ml/min. The effluent was collected, and the PTHrP concentration was measured. In a subgroup of experiments, the endothelial cell compartment was carefully denuded by a 5-s perfusion with standard buffer containing Triton X-100 (0.5% vol/vol). In another subgroup of experiments, the viscosity of the perfusion buffer was increased by addition of 10% (wt/vol) dextran (mol mass 50 kDa). Finally, PTHrP release was determined in a further group of experiments, in which either arginine (100 mol/l) or N -nitro-L-arginine (L-NNA, 100 mol/l) was added. In vivo experiments were performed on male Göttinger minipigs (20-40 kg) as described previously (7) . Animals were initially sedated with ketamine hydrochloride (1 g im) and then anesthesized with thiopental sodium (Trapanal, 500 mg iv). The trachea was intubated through a midline cervical incision for connection to a respirator (Drä ger, Lü -beck, Germany). Anesthesia was then maintained with enflurane (1.0-1.5%) with an O 2-N2O mixture (40%-60%). Both common carotid arteries and internal jugular veins were isolated through the cervical incision and cannulated with polyethylene catheters, one for measuring the arterial pressure and the other to supply blood to the extracorporal circuit. The jugular veins were cannulated for volume replacement with warmed 0.9% (wt/vol) NaCl and for the return of blood to the animal from the coronary venous line. The left anterior descending coronary artery (LAD) was dissected over a distance of 1.5 cm, ligated, cannulated, and perfused from an extracorporal circuit. Before coronary cannulation, the swine were anticoagulated with 20,000 IU of heparin sodium; additional doses of 10,000 IU were given at hourly intervals. Coronary arterial pressure was measured from the sidearm of a polyethylene T connector (ColeParmer, Chicago, IL) used as a catheter tip with an external transducer (type 4-3271, Bell and Howell, Pasadena, CA). The large epicardial vein parallel to the LAD was dissected and cannulated. Coronary venous blood was drained to an unpressurized reservoir and then returned to a jugular vein. Heart rate was controlled throughout the study by left atrial pacing (type 215/T; Hugo Sachs Elektronik, Hugstetten, Germany). The complete preparation was allowed to stabilize for at least 30 min before control measurements were made. The constant-flow perfusion pump was adjusted so that the minimum coronary arterial pressure was Ͼ70 mmHg under control conditions to avoid hypoperfusion. In a first set of experiments, PTHrP release was determined under basal conditions and 5 min after a flow reduction. In a second set of experiments, 1 g of bradykinin was infused into the extracorporal circuit at a constant perfusion pressure. Blood samples were collected from the cavum of the left ventricle to determine the arterial PTHrP plasma concentration and from the large epicardial vein parallel to the LAD to determine the coronary venous plasma concentration. PTHrP release was calculated from the arterial-coronary venous difference of the plasma PTHrP concentrations.
Endothelial cell preparations. Coronary endothelial cells were isolated from 250-g male Wistar rats and grown in culture as previously described (15) . Briefly, hearts were perfused with collagenase, chopped, and dissolved into a suspension. From this suspension, the fraction of endothelial cells was purified. Cells were plated at a density of 10 6 cells/dish on 100-mm plastic petri dishes. The cells were incubated at 37°C in medium 199 with Earle's salts, supplemented with 100 IU/ml penicillin G, 100 g/ml streptomycin, and 10% (vol/vol) fetal bovine serum. The medium was renewed every second day. After 4 days, when the cells had grown to confluence, they were trypsinized in PBS [in mmol/l: 137 NaCl, 2.7 KCl, 1.5 KH2PO4, and 8 Na2HPO4 at pH 7.4, supplemented with 0.05% (wt/vol) trypsin and 0.02% (wt/vol) EDTA] and seeded at a density of 4 ϫ 10 5 cells/cm 2 on collagen-coated silicone dishes. As previously reported (14) , the purity of these cultures was Ͼ95% endothelial cells as determined by uptake of acetylated low-density lipoprotein labeled with 1,1Ј-dioctadecyl-3,3,3Ј,3Ј-tetramethyl-indocarbocyanine perchlorate, contrasted by Ͻ5% cells positive for ␣-smooth muscle actin. Experiments were started 2 days later by exposing the cells to cyclic strain (5-20%) at a constant frequency of 1 Hz. After 1 h, experiments were terminated and supernatants and cell extracts were used to determine PTHrP expression or release.
Analytic methods. During rat heart perfusion, 1-ml samples of the effluent were collected at the indicated times as described previously (17) . To these samples, 100 l of deoxycholate (100 mmol/l) for 10 min and thereafter 100 l of trichloroacetic acid (100%) were added. Samples were kept for 30 min at 4°C. Proteins were precipitated by centrifugation (5 min, 13,000 g), and the pellet was redissolved in 35 l of electrophoresis sample buffer [0.5 mmol/l Tris ⅐ HCl, 4% (wt/vol) SDS, 25% (vol/vol) glycerin, 1% (vol/vol) mercaptopropanediol, and 0.1% (wt/vol) bromophenol blue; pH 6.8] and heated at 65°C for 10 min. The pH was adjusted to 7 by the addition of 100% Tris. Plasma samples from swine were diluted 1:10 (vol/vol) with H2O, and 100 l of this dilution were prepared as described above for the effluent of salineperfused rat hearts. Supernatants of cell cultures were used as described for the effluent of the perfused rat hearts. Cell samples were prepared as described previously (17) . Briefly, cells were washed with ice-cold PBS, homogenized by the addition of 100 l of lysis buffer [50 mmol/l Tris ⅐ HCl, 2% (wt/vol) SDS, 2% (vol/vol) mercaptopropranediol, and 1 mmol/l Na3VO4; pH 6.7] . The dishes were shaken vigorously for 10 min. Thereafter, 10 l benzonase (50 U/ml) was added and the samples were shaken again for 10 min. Finally, samples were removed with the aid of a rubber policeman, filled in a reaction tube, mixed with 100 l of electrophoresis sample buffer, and heated at 65°C for 10 min.
PTHrP concentrations were measured in these samples by performing a nonradioactive immunoassay with alkaline phosphatase. Appropriate amounts of samples (35 l of effluents, plasma samples, or culture supernatants) or samples containing 60 g of protein (endothelial cells) were used for SDS-PAGE containing 12.5% (wt/vol) polyacrylamide. Electrophoretically separated proteins were transblotted on polyvinylidene difluoride (PVDF) membranes. After transfer, PVDF membranes were blocked with 2% (wt/vol) bovine serum albumin in Tris buffer (30 mmol/l; pH 7.4) overnight and incubated with antibodies directed against PTHrP [antibody GF08, Oncogene Research Products; purchased from Calbiochem, Bad Soden, Germany; directed against PTHrP-(38-64)] for 2 h. After incubation, the PVDF membranes were washed in 30 mmol/l Tris buffer (pH 7.4) and exposed to an alkaline phosphatase-coupled second antibody for 2 h. Finally, proteins were visualized with the use of 5-bromo-4-chloro-3-indolyl phosphate-nitro blue tetrazolium as alkaline phosphatase substrates. Densitometry on protein immunoblots was performed with Image Quant (Molecular Dynamics, Krefeld, Germany). The system was standardized by full-length PTHrP purified from coronary endothelial cells as described previously (17) .
Nitrite concentrations in the perfusate were determined as described previously (9) . The nitrite content in the supernatant was measured by combining 500 l of perfusate with 500 l of Griess reagent (0.75% sulfanilamide in 0.5 N HCl-0.075% naphthylethylenediamine), and the concentration of the resulting chromophore was determined spectrophotometrically at 543 nm. Lactate dehydrogenase activities in the perfusate were photometrically determined as described previously (18) .
Determination of coronary resistance in isolated, perfused rat heart preparations. Isolated rat hearts were perfused as described above in the Langendorff mode. In the perfusion buffer, the concentration of KCl was corrected from 27 to 2.7 mmol/l to allow the hearts to beat. Hearts were paced at a constant frequency of 3 Hz and perfused at a constant pressure of 55 mmHg. At the indicated time, the effluent was collected for 1 min and the volume was measured. Coronary resistance was calculated from the perfusion pressure and calculated coronary flow and normalized to heart wet weight.
Statistics. Quantitative results are expressed as means Ϯ SE. In experiments with more than two groups, ANOVA was used for comparison, with a Student-Newman-Keuls test for post hoc analysis. In cases in which two groups were compared, conventional t-tests were performed. A P Ͻ 0.05 indicated a significant difference between groups.
RESULTS
PTHrP release from isolated, saline-perfused rat hearts. In the effluent of hearts isolated from adult rats perfused at a constant flow of 5 ml/min under nonbeating conditions, 84.3 Ϯ 8.3 ng PTHrP/ml was detected, corresponding to a concentration of 1.7 nmol/l. The basal release rate was 422 Ϯ 42 ng PTHrP/min (n ϭ 8). Increases or decreases in coronary flow were rapidly followed by concomitant changes in the release rate of PTHrP (Fig. 1A) . The data of coronary flow and PTHrP release were positively correlated (Fig. 1B) . As a result of this flow-dependent adaptation, PTHrP concentration in the effluent remained nearly constant (Fig. 1C) . No significant release of lactate dehydrogenase was detectable.
In a further set of experiments, denudation of the endothelial cell compartment by the addition of Triton X-100 to the perfusate resulted in a significant loss of basal and flow-dependent PTHrP release (Fig. 2 ).
An increase in the viscosity of the perfusate by addition of dextran at a constant flow did not influence basal PTHrP release (Fig. 3) . This maneuver changed shear stress, as indicated by an enhanced nitrite production (ϩ23 Ϯ 5% over basal; P Ͻ 0.05 vs. control; n ϭ 4).
In a further set of experiments PTHrP release was determined under conditions in which flow was increased but pressure was held constant. This was achieved by addition of the NO donor spermine-NONOate (100 nM). Under these conditions, no significant increase of PTHrP release could be detected (Fig. 4A) . Similar results were also depicted with arginine, which enhanced endothelial NO release and increased flow by 14 Ϯ 6% but did not change PTHrP release [212 Ϯ 33 to 213 Ϯ 20 ng/min; n ϭ 4; not significant (NS)]. However, when the NO donor was given under conditions under which the flow was kept constant, it caused a decrease of perfusion pressure and PTHrP release decreased (Fig. 4B) .
In a final set of experiments in isolated rat hearts perfused at a constant flow of 5 ml/min, addition of L-NNA reduced, whereas addition of arginine increased, nitrate production (Table 1) . However, neither L-NNA nor arginine changed PTHrP release, irrespective of their effect on NO release.
Influence of PTHrP on coronary resistance. Isolated rat heart vessels were preconstricted by perfusion with the ␣-adrenoceptor agonist phenylephrine. In the presence of phenylephrine, coronary resistance was increased from 8.87 Ϯ 0.34 to 10.83 Ϯ 0.19 mmHg ⅐ ml Ϫ1 ⅐ g. Synthetic PTHrP-(1-34) or authentic PTHrP, which was purified from the plasma samples of the pigs, induced vasodilation, indicating functional PTHrP receptors ( 3.1 Ϯ 0.3 to 1.0 Ϯ 0.1 mmHg ⅐ ml Ϫ1 ⅐ min (n ϭ 3; P Ͻ 0.05) in pig hearts.
PTHrP release from isolated coronary endothelial cells under cyclic strain. In isolated coronary endothelial cells exposed to increasing degrees of cyclic strain, to mimic the mechanical influence of blood pressure on these cells, PTHrP release was directly related to the degree of cyclic strain (Fig. 5) . Preincubation of coronary endothelial cells with the calcium-chelating agent BAPTA prevented the cyclic strain-dependent release of PTHrP (Fig. 6) , suggesting a calcium-dependent mechanism.
The effect of cyclic strain on PTHrP release from coronary endothelial cells was finally compared with cultured smooth muscle cells, which is another important cell type in the vascular bed that expresses PTHrP. As indicated on the illustrating immunoblot, both cell types express PTHrP (Fig. 7) . However, cyclic strain caused a release of PTHrP from coronary endothelial cells but not from cultured smooth muscle cells (Fig. 7) .
Release of PTHrP in vivo from coronary vascular bed. In anesthesized pigs, arterial PTHrP concentration amounted to 277.9 Ϯ 54.8 ng PTHrP/ml and coronary venous PTHrP concentration to 423.9 Ϯ 56.8 ng PTHrP/ml, corresponding to 5.6 and 8.5 nmol/l, respectively. The coronary venous-arterial difference therefore averaged 146.0 Ϯ 32.7 ng PTHrP/ml (n ϭ 15 pigs), indicating a constant PTHrP release from the coronary vascular bed under in vivo conditions. Fig. 2 . PTHrP release from isolated, saline-perfused nonbeating rat hearts at perfusion rates of 5 and 10 ml/min. Hearts were perfused before (open bars) and after (filled bars) denudation by 5-s perfusion with 0.5% (vol/vol) Triton X-100 added to the perfusion buffer. Data are means Ϯ SE from n ϭ 4 hearts. *P Ͻ 0.05 between 5 and 10 ml/min flow; #P Ͻ 0.05 vs. release rate at 5 ml/min before denudation of the endothelial cell compartment. Fig. 3 . PTHrP release from isolated, saline-perfused nonbeating rat hearts. Actual PTHrP release rate is expressed in pg PTHrP/min and shown during 1 representative experiment in which the perfusion rate was kept constant at 5 ml/min. As indicated at top, dextran (10% wt/vol) was added to the perfusate after 10 min and washed out again after 30 min. Inset: mean PTHrP release rate under control conditions (C) and 5 min after addition of dextran (D; 10% wt/vol). n.s., Not significant. hearts were perfused at a constant coronary pressure for 10 min for stabilization. Thereafter, the nitric oxide (NO) donor spermineNONOate (100 nM) was added. Bars indicate changes observed 5 min after addition of spermine-NONOate. The 100% values are 55 mmHg for coronary perfusion pressure (P), 6.39 Ϯ 0.16 ml/min for coronary flow (F), and 124 Ϯ 36 ng PTHrP/min for PTHrP release (R). B: hearts were perfused with a constant coronary flow for 10 min for stabilization. Thereafter, the NO donor spermine-NONOate (100 nM) was added. Bars indicate the changes observed 5 min after addition of spermine-NONOate. The 100% values are 53.4 Ϯ 2.9 mmHg for coronary perfusion pressure, 10 ml/min for coronary flow, and 165 Ϯ 78 ng PTHrP/min for PTHrP release. Data are means Ϯ SE. *P Ͻ 0.05 vs. end of stabilization period (n ϭ 4). Values are means Ϯ SE; n ϭ no. of hearts. Nitrite and parathyroid hormone-related peptide (PTHrP) concentrations were determined in the effluent of isolated, saline-perfused nonbeating rat hearts 10 min after the addition of the agonists. Effluents were collected from hearts perfused with untreated perfusion buffer, after the addition of arginine (100 mol/l) or the addition of N -nitro-L-arginine (L-NNA; 100 mol/l) at 5 ml/min. * P Ͻ 0.05 vs. control at 5 ml/min.
After baseline measurements with a flow rate resulting in a mean coronary arterial pressure of 111 Ϯ 4 mmHg, the coronary flow was reduced to ϳ29% of its initial value. The hemodynamics are given in Table 3 . PTHrP release was calculated again from the plasma concentrations in the arterial and coronary venous blood samples 5 min after flow reduction. In all hearts, reduction in coronary flow was followed by a reduced PTHrP release (Fig. 8) .
In another set of experiments, addition of L-NNA at a constant inflow (29 Ϯ 8 vs. 31 Ϯ 7 ml/min) increased coronary resistance from 3.10 Ϯ 0.74 to 4.20 Ϯ 1.19 mmHg ⅐ ml Ϫ1 ⅐ min. Similar to the in vitro results, addition of L-NNA under these conditions did not change PTHrP release (4.28 Ϯ 1.91 vs. 4.49 Ϯ 6.71 g PTHrP/; n ϭ 6 pigs; NS).
Influence of bradykinin on PTHrP release. Because the data on the mechanosensitive release of PTHrP from the vascular bed suggest a calcium-dependent mechanism, we finally investigated whether an increase in intracellular calcium concentration caused by the addition of bradykinin mimics the effects of mechanotransduction. In isolated and cultured coronary endothelial cells, bradykinin (10 mol/l) caused a net release of PTHrP of 4.01 Ϯ 0.83 pg/g protein. In the isolated, perfused rat heart system, bradykinin caused an increase in flow of 39.7% and an increase in PTHrP release of 51.3% (Fig. 9A) . Under in vivo conditions in the pig heart, bradykinin increased flow to 150.5% and Data are means Ϯ SE; n ϭ no. of hearts. Isolated rat hearts were perfused with a constant perfusion pressure (55 mmHg) and paced at a constant frequency of 3 Hz. Coronary resistance was calculated by the quotient of perfusion pressure and perfusion flow normalized to heart weight. Basal coronary resistance amounted to 8.87 Ϯ 0.34 mmHg ⅐ ml Ϫ1 ⅐ g. Before PTHrP fragments were added, coronary resistance was increased by addition of phenylephrine (10 mol/l). After 5 min, a stable coronary resistance had developed and synthetic PTHrP-(1-34), synthetic PTH-(7-34), or authentic PTHrP, which was purified from pig plasma via immunoprecipitation, was added (each 100 nmol/l). *P Ͻ 0.05 vs. phenylephrine. Fig. 5 . PTHrP release from coronary endothelial cells grown on flexible silicone dishes and exposed to cyclic strain (0%, 5%, 10%, and 20% at 1 Hz) for 1 h. PTHrP concentration was determined in the supernatant and normalized to the cellular protein content of the dishes. Data are means Ϯ SE from n ϭ 6 dishes. Fig. 6 . PTHrP release from coronary endothelial cells grown on flexible silicone dishes and exposed to 0% or 10% cyclic strain (1 Hz) for 1 h. PTHrP concentration was determined in the supernatant and normalized to the cellular protein content of the dishes. Where indicated, cultures were pretreated with the calcium-chelating agent BAPTA (10 mol/l) before exposure to cyclic strain. Data are means Ϯ SE from n ϭ 9 dishes. PTHrP release by 73% (Fig. 9B) . In both set of experiments, perfusion pressure was held constant to void mechanosensitive release of PTHrP.
DISCUSSION
The main findings of the present study are 1) PTHrP is constantly released from the coronary vascular bed under in vitro and in vivo conditions, 2) the release rate is changed in response to mechanical stress via intracellular calcium, and 3) alterations in flow are sufficient to induce a mechanosensitive release of PTHrP from the vascular bed. Shear stress seems not to be the mediator of this response. Finally, the basal PTHrP release is physiologically relevant, because inhibition of its biological activity by the addition of a PTHrP receptor antagonist increases coronary resistance.
Nonmalignant cells, which express PTHrP, require a certain kind of trigger for the release of the peptide. Therefore, systemic plasma levels of PTHrP in humans are normally low, although PTHrP is expressed in many cell types throughout the body. In agreement with these observations, cultures of coronary endothelial cells do not release PTHrP under no-flow conditions (17) . In the present study, a significant correlation between flow and PTHrP release rate was found in saline-perfused rat hearts. Moreover, we demonstrated a net release from the coronary vascular bed in vivo, and this release was also modified by flow variations. All these observations strongly suggest that PTHrP, expressed in the vascular bed of the heart (6, 17) , participates in the regulation of coronary flow and, indeed, blockade of the PTHrP receptor increases coronary resistance in vitro.
Blood flow generates distinct types of forces on the vascular bed (3). Our finding that an increase in perfusate viscosity does not increase basal PTHrP release suggests that shear stress is not involved in the mechanism causing the flow-dependent PTHrP release. This conclusion is further supported by the finding that the NO donor reduced PTHrP release under constant-flow conditions, when it caused a reduction in coronary perfusion pressure, but did not increase PTHrP release under constant-pressure conditions, under which flow was increased. In line with this assumption, coronary endothelial cells released PTHrP in vitro when exposed to cyclic strain, which evokes a passive load on the cell layer. Cyclic strain leads to an increase of intracellular calcium (16) . This increase in intracellular calcium seems to be the trigger for PTHrP release from coronary endothelial cells, because in the presence of BAPTA, no release of PTHrP was observed. In accordance with Values are means Ϯ SE. LVPP, left ventricular peak pressure; CAP, mean coronary arterial pressure; CBF, mean coronary blood flow; CR, coronary resistance; LV dP/dtmax (LV dP/dtmin), maximum (minimum) of 1st derivative of left ventricular pressure; HR, heart rate. * P Ͻ 0.05 vs. basal. these findings, bradykinin, which also increases intracellular calcium concentration in endothelial cells, caused PTHrP release from isolated coronary endothelial cells held under no-flow conditions, from isolated, perfused rat hearts, and in vivo (pig hearts). In the latter experiments, perfusion pressure was held constant to void mechanosensitive release. We (17) found previously that the coronary endothelial cells can release PTHrP under hypoxic conditions. It is interesting that under these conditions, intracellular calcium is also elevated (12) , suggesting a common mechanism for PTHrP release from coronary endothelial cells under all three conditions. Endothelial cells are directly exposed to mechanical forces generated by blood flow. Indeed, endothelial cells seem to contribute significantly to PTHrP released from isolated, perfused rat hearts, because basal PTHrP release and flow-dependent changes were reduced after denudation of the endothelium. Moreover, isolated and cultured endothelial cells, but not smooth muscle cells, released PTHrP under constant cyclic strain. Together, these results suggest that PTHrP is constantly released from the endothelial cell compartment in hearts in a flow-dependent manner. However, participation of other cell types in basal PTHrP release, like smooth muscle cells, cannot be excluded from these experiments.
We (19) recently showed that PTHrP expression is reduced or diminished in elderly spontaneously hypertensive rats. Under these conditions, basal coronary flow is also reduced (10) . This might suggest that PTHrP, in addition to other known factors, contributes to the dysregulation of basal coronary flow in spontaneously hypertensive rats. In addition, PTHrP is released under energy-depleting conditions, pointing to a potential role for PTHrP in the hyperemic response of the heart after ischemia.
The coronary flow is regulated by various local vasoactive dilating factors. Of particular interest is the role of endogenous NO as it impairs the release of EDHF (1) . A direct influence of NO on PTHrP release was not observed. Under constant-pressure conditions the NO donor or arginine increased flow but PTHrP release was not modified. Under constant-flow conditions, the NO donor caused a drop in perfusion pressure and a subsequent reduction in PTHrP release. This indicates that changes in perfusion pressure modify PTHrP release but not NO itself. Therefore, any alterations in the activity or expression of NO synthase under pathophysiological conditions will not necessarily impair the role of PTHrP in the regulation of coronary flow.
We are aware of the fact that reductions of flow might also induce an ischemia-dependent release of PTHrP. Although we (17) showed previously that coronary endothelial cells release PTHrP under energy-depleting conditions, this does not seem to play a role in the present study. The time for which we reduced flow (5 min) was too small to induce ischemiadependent PTHrP release (30 min; Ref. 6). Similar concerns hold for the pig model, in which ischemiadependent release of PTHrP could not be seen within the first 60 min under the apparent conditions (flow reduction to 10% of basal). Nevertheless, prolonged ischemia will necessarily lead to a situation in which factors associated with ischemia alter the release of the peptide as well.
In summary, our study provides direct evidence for a mechanosensitive release of PTHrP from the vascular bed. The data suggest that alterations in flow might change the local concentration of PTHrP.
